Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of MK-3120 in Advanced Solid Tumors
2024-516817-19-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- May 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, open-label, single-arm trial of MK-3120 in advanced nonhematological malignancy, Metastatic solid neoplasm and cancer, sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experience an Adverse Event (AE) and Number of Participants Who Discontinue Study Treatment Due to an AE. Planned start May 2025; status: authorised.
02
Drugs
MK-3120
03
Conditions
advanced nonhematological malignancyMetastatic solid neoplasmcancer
Beyond the preview
Go deeper on 2024-516817-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516817-19-00.